Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00273338 · ClinicalTrials.gov registry record · Phase 3
DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])
A Phase 3 study, sponsored by Novacea.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,200
- Enrollment target
NCT00273338 is a Phase 3 study that was terminated before completion, run by Novacea. The registered enrollment target is 1,200 participants.
The verdict
NCT00273338, a Phase 3 study, was terminated before completion, sponsored by Novacea.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,200 participants
- Enrollment target
Study Summary
The primary objective of this study is: * To evaluate the effect of DN-101 in combination with docetaxel (ASCENT regimen) on survival in metastatic androgen-independent prostate cancer The secondary objectives of this study are: * To determine the effect of the ASCENT regimen on the rate of thromboembolic events (blood clots) * To determine the effect of the ASCENT regimen on prevention of skeletal-related events (fractures) * A Separate sub-study will be conducted at selected study sites in North America to determine the population PK of DN-101.
Interventions
- DRUG docetaxel
- DRUG calcitriol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00273338
The ClinicalTrials.gov registry entry for NCT00273338 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novacea, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which docetaxel is the first listed.
NCT00273338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00273338 about?
NCT00273338 is a clinical study titled "DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])". The primary objective of this study is: * To evaluate the effect of DN-101 in combination with docetaxel (ASCENT regimen) on survival in metastatic androgen-independent prostate cancer The secondary objectives of this study are: * To determine the effect of the ASCENT regimen on the rate of throm...
What is the current status of trial NCT00273338?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,200 participants. The study started on 2006-01. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00273338?
The interventions under investigation include: docetaxel (DRUG), calcitriol (DRUG).
Who is sponsoring clinical trial NCT00273338?
This trial is sponsored by Novacea, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.